A trial looking at the safety of an Ebola vaccine has had encouraging results, says the chief executive of GSK.
Sir Andrew Witty said new clinical data was "very encouraging" and that a viable vaccine could be available in the second half of next year - if these early trials continue to provide positive results.
The National Institutes of Health (NIH) in America has just released the first trial data for the vaccine that GSK is working on in its laboratories in Italy and Belgium.
Twenty adults were tested and an immune response to Ebola was prompted in each of them. The vaccine was also "well tolerated" by each of the people tested.
No comments :
Post a Comment